Sign up USA
Proactive Investors - Run By Investors For Investors

ContraVir Pharmaceuticals Inc’s drug study design impresses Maxim analysts

Its drug CRV431 is being developed to treat liver tumors in patients with hepatitis B
Scientist
Maxim analysts reiterated a Hold rating following the FDA's decision

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) announced that it will begin its first clinical studies for its drug CRV431 after the US Food and Drug Administration accepts its Investigational New Drug application.

Clinical development will begin on CRV431, which is intended to reduce the size of liver tumors in patients with hepatitis B by inhibiting cyclophilin isomerase activity. Viruses use cyclophilin to replicate themselves.

READ: ContraVir Pharmaceuticals surges on positive results for its liver cancer treatment

Hepatocellular carcinoma is the most common type of primary liver cancer in people and the leading cause of death in people with cirrhosis.

“The FDA’s approval of our development strategy in accelerating the clinical development of CRV431 allows us to move into patient trials in an expedited manner,” said CEO James Sapirstein in a press release.

The partially-blind, placebo-controlled study will be conducted in the U.S. with participation from hepatitis B patients.

Study design is key

Maxim analysts viewed the FDA approval as a pathway to an accelerated timeline.

The trial is set up in three parts and will test healthy subjects as well as patients with hepatitis B. This design may eliminate a need for separate single drug studies and the company can instead move straight to combination studies.

Maxim analysts maintained a Hold rating on the biotech.

Shares of the New Jersey-based company were up more than 4% to US$1.51 Thursday afternoon after jumping as high as 15% in early trading.

--Updated to include analyst note

View full CTRV profile View Profile

ContraVir Pharmaceuticals Timeline

Related Articles

picture of oilfield
March 14 2018
Svetlana Mendesh, Chief Financial Officer, said 2016 results were in line with its projections and local market trends.
Hong Kong harbour
Mon
The transition of the business through the diversification of legacy assets and investing in new opportunities in Asia is well underway, said chairman John Croft
Enertopia Corp's partner GWT upbeat on potential of lithium recovery tests
October 25 2017
The feedstock used in the tests comes from the group's Clayton valley project in Nevada

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use